An interventional study of 80 lead ECG in Arrhythmogenic Right Ventricular Cardiomyopathy, sponsored by The Leeds Teaching Hospitals NHS Trust. Completed. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-19.
Sponsored by The Leeds Teaching Hospitals NHS Trust · Not applicable, Interventional, and Diagnostic
The diagnosis of Arrhythmogenic right ventricular cardiomyopathy can be difficult. The 80 lead ECG may increase the specificity and sensitivity in diagnosing this potentially life threatening inherited cardiac condition. This pilot would form the basis of a much larger clinical trial to test the utility of this novel diagnostic tool.
1,176 studies on the registry are indexed under Cardiomyopathies; 287 are open to participants now.
This study's enrollment of 20 is below the median of 51 across 609 interventional studies indexed under Cardiomyopathies.
Browse Cardiomyopathies studies →The Leeds Teaching Hospitals NHS Trust is the lead sponsor of 95 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients with previously confirmed Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
Device: 80 lead ECG
Aged and gender matched healthy controls.
Device: 80 lead ECG
QRS wave dispersion in an ECG
The difference in QRS wave dispersion between the right and left ventricular leads
Time frame: 5 minutes
No study locations are listed for this record.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Leeds Teaching Hospitals NHS Trust